Ji Xue Teng

Spatholobus suberectus Dunn is the sole official source of Ji Xue Teng in the Chinese Pharmacopoeia, but several red-sapped climbing stems are traded under the same or similar names and substitution is common enough that molecular and metabolomic authentication methods have been developed specifically for it. The evidence is not uniform across the substitutes, and it is worth grading. Untargeted UHPLC-Q-Orbitrap HRMS profiling that identified 1157 compounds separated authentic S. suberectus from Mucuna macrocarpa, Callerya dielsiana and Kadsura heteroclita on flavonoid and phenolic acid pathways; those three are the best documented. Mucuna birdwoodiana is among the further species that rbcL and ITS2 barcoding work sets out to exclude. Sargentodoxa cuneata is reported as a confusable species in the authentication literature, much of it Chinese-language and not verified here against a primary source, so it should be treated as a plausible but less firmly established substitute than the other four. The chemical distance matters in every case: Kadsura heteroclita is a Schisandraceae vine whose chemistry is lignans and triterpenoids rather than isoflavones, and Sargentodoxa cuneata is Hong Teng, a separate Pharmacopoeia drug in its own right that clears heat and resolves toxin for intestinal abscess rather than nourishing blood. A patient given either receives a pharmacologically unrelated drug under the name Ji Xue Teng.

Ethanolic extracts of the vine stem have been reported to reduce platelet aggregation and to inhibit fibrinogen formation, with thromboxane A and glycoprotein IIb/IIIa receptor involvement described in review summaries of the preclinical literature. This is consistent with the herb's traditional blood-invigorating action. No human pharmacodynamic study, no INR data and no bleeding case series exist for this drug, so the effect size in a treated patient is unknown.

The main constituents of the vine stem are flavonoids classifiable as phytoestrogens with structures similar to estrogen, and a column extract of the herb was tested directly on the estrogen-receptor-positive MCF-7 line, where it reduced cell viability at 80, 160 and 320 micrograms per millilitre by suppressing ER, MAPK and PI3K/AKT signalling. The important point for practice is that the direction of the effect is not the naive one: this phytoestrogen-rich drug suppressed rather than stimulated an ER-positive line in vitro. Because neither direction has been shown in a patient, the interaction with endocrine therapy remains unpredictable rather than reassuring.

The vine stem is rich in catechins and condensed proanthocyanidins, and tannins of this class are well established to chelate non-haem iron in the gut lumen and reduce its absorption. The interaction has not been measured for this specific drug. It matters clinically because the herb's main indication, blood deficiency with pallor and dizziness, is exactly the presentation in which a patient is likely to also be taking an iron supplement.